glp-1 news today october 16 2025 ISPOR 2025: Exploring reasons for discontinuation GLP-1 Weight-Loss Drug Demonstration Begins

We've also made appointments with their medical professionals, received medicine, and tried it for ourselves

In patients with newly diagnosed T2DM, Tong et al

Watanabe, J., Asaka, Y., and Kanamura, S

Contact your healthcare provider promptly if you experience: Excessive fatigue or weakness Rapid or unexplained weight loss exceeding expected rates Severe, persistent abdominal pain (which may indicate pancreatitis) Persistent vomiting or signs of dehydration New or worsening visual symptoms (particularly if you have diabetic retinopathy) Difficulty maintaining basic daily activities Your healthcare team can assess whether metabolic changes are within expected parameters and adjust your treatment plan accordingly